Oncogenic LncRNA CASC9 in Cancer Progression

Author(s): Yuying Qi, Chaoying Song, Jiali Zhang, Chong Guo*, Chengfu Yuan*

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 4 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Long non-coding RNAs (LncRNAs), with the length of over 200 nucleotides, that originate from intergenic, antisense, or promoter-proximal regions, are a large family of RNAs that lack coding capacity. Emerging evidences illustrated that LncRNAs played significant roles in a variety of cellular functions and biological processes in profuse human diseases, especially in cancers. Cancer susceptibility candidate 9 (CASC9), as a member of the LncRNAs group, firstly found its oncogenic function in esophageal cancer. In the following recent studies, a growing amount of human malignancies are verified to be correlated with CASC9, most of which are derived from the squamous epithelium tissue. This present review attempts to highlight the latest insights into the expression, functional roles, and molecular mechanisms of CASC9 in different human malignancies.

Methods: In this review, the latest findings related to the pathophysiological processes of CASC9 in human cancers were summarized and analyzed, and the associated studies collected in systematic retrieval of PubMed used lncRNA and CASA9 as keywords.

Results: CASC9 expression is identified to be aberrantly elevated in a variety of malignancies. The over-expression of CASC9 has been suggested to accelerate cell proliferation, migration, cell growth and drug resistance of cancer cells, while depressing cell apoptosis, revealing its role as an oncogene. Moreover, the current review demonstrated CASC9 as closely related to the neoplastic transformation of squamous epithelial cells and squamous metaplasia in non-squamous epithelial tissues. Finally, we discuss the limitations and tremendous diagnostic/ therapeutic potential of CASC9 in various human cancers.

Conclusion: Long non-coding RNA CASC9 likely serve as useful disease biomarkers or therapeutic targets which be effectively applied in the treatment of different kinds of cancers.

Keywords: LncRNAs, cancer susceptibility candidate 9 (CASC9), cancers, biomarkers, intergenic, antisense, promoter-proximal regions.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 4
Year: 2021
Published on: 03 March, 2021
Page: [575 - 582]
Pages: 8
DOI: 10.2174/1381612826666200917150130
Price: $65

Article Metrics

PDF: 58